

The board of directors' complete resolution proposal in respect of an authorisation for the board of directors to issue new shares (item 13)

The board of directors of Sedana Medical AB (publ), reg. no. 556670-2519, proposes that the annual general meeting resolves on an authorisation for the board of directors to, at one or more occasions during the period until the next annual general meeting, with or without deviation from the shareholders' preferential rights, resolve upon new share issues. By new share issue resolutions made by exercise of the authorisation, with deviation from the shareholders' preferential rights, the company's share capital may not be increased by an amount exceeding ten (10) per cent of the share capital in the company as of the date of the annual general meeting. A new share issue resolved by exercise of the authorization may be made with or without stipulations regarding non-cash consideration, set-off or other conditions referred to in Chapter 13, Section 5, first paragraph, item 6 of the Swedish Companies Act (2005:551).

The objective of the authorisation is to provide the board of directors with flexibility in its work to ensure that the company can procure capital for the financing of the operations in an appropriate manner, to enable business or company acquisitions and to enable a broadening of the company's shareholder base.

The chairman of the board of directors, the CEO, or any person appointed by either of them, shall be authorised to make such minor adjustments to the resolution as may be required in connection with the registration with the Swedish Companies Registration Office (Sw. Bolagsverket).

A valid resolution requires that the proposal is supported by at least two-thirds of the votes cast as well as of all shares represented at the meeting.

Danderyd in April 2021
Sedana Medical AB (publ)
The board of directors